ResMed Inc. 10-Q Summary: Quarter Ended September 30, 2007
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2007 for ResMed Inc., a leading developer and manufacturer of medical equipment for sleep-disordered breathing and respiratory disorders. The company operates manufacturing facilities in Australia, France, and the United States, with global distribution networks. As of November 1, 2007, there were 77,302,180 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2007 | Q3 2006 |
|---|---|---|
| Net Revenues | $185.7 million | $163.6 million |
| Gross Profit | $111.8 million | $101.3 million |
| Gross Margin | 60.2% | 62.0% |
| Net Income | $24.1 million | $25.0 million |
| Diluted EPS | $0.31 | $0.32 |
| Operating Cash Flow | $28.1 million | $26.1 million |
| Cash & Equivalents | $251.3 million | $201.2 million |
| Total Debt (Current + Long-term) | $115.9 million | Filing text does not provide clear Q3 2006 total debt figure |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 14% year-over-year, driven by higher unit sales of flow generators, masks, and accessories. International sales grew 19%, aided by favorable currency movements ($6.1 million positive impact).
- Margin Compression: Gross margin declined from 62% to 60%. This was primarily due to reduced average selling prices and higher manufacturing costs in Australia resulting from a stronger Australian dollar.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 18% to $62.9 million, largely due to increased personnel and currency impacts. R&D expenses increased 20% to $13.0 million.
- Restructuring: The company incurred $2.3 million in restructuring expenses related to streamlining European management and closing regional offices, compared to none in the prior year.
- Recall Liability: A remaining liability of $26.6 million exists for the voluntary recall of S8 flow generators initiated in April 2007 (total estimated cost $59.7 million).
Outlook, Risks, and Management Commentary
- Guidance: Management expects SG&A expenses to remain in the 32% to 34% range of net revenue and R&D expenses to remain at approximately 7%.
- Capital Projects: Significant construction is underway for a new corporate headquarters in San Diego (estimated remaining cost $88.1 million) and an extension of the Sydney manufacturing facility (estimated remaining cost $3.5 million).
- Liquidity: The company maintains strong liquidity with $277.8 million in cash and marketable securities. It has a $70 million undrawn revolving credit facility and is in compliance with all debt covenants.
- Risks: Key risks include foreign currency exchange rate fluctuations, potential changes in reimbursement policies, and the execution of the ongoing product recall. The company utilizes foreign currency options to hedge exposure.
- Legal: Ongoing litigation includes a patent inventorship dispute in Germany and a breach of license agreement claim by an Australian university; management does not expect these to have a material adverse effect.
Investor Verification Checklist
- Verify the progress and cost containment of the S8 flow generator recall ($26.6 million remaining liability).
- Monitor the impact of the Australian dollar strength on future gross margins given the concentration of manufacturing costs in Australia.
- Review the timeline and funding sources for the San Diego headquarters construction ($88.1 million remaining).
- Assess the sustainability of international revenue growth excluding the one-time benefit of favorable currency movements.
- Confirm compliance with debt covenants (Debt-to-EBITDA, fixed charge coverage) as the company carries $115.9 million in debt.